论文部分内容阅读
目的:探讨蛋白质磷酸酶2A癌性抑制因子(cancerous inhibitor of protein phosphatase2A,CIP2A)在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达及其临床意义。方法:应用免疫组织化学法检测97例NSCLC组织及其相应癌旁组织中CIP2A蛋白的表达情况,分析CIP2A蛋白表达与NSCLC患者临床病理特征及预后之间的关系。结果:NSCLC组织中CIP2A蛋白的阳性表达率[76.3%(74/97)]明显高于其相应的癌旁组织[5.2%(5/97)],差异有统计学意义(P<0.01)。CIP2A蛋白阳性表达与NSCLC患者的年龄、性别、吸烟情况、组织学类型、TNM分期、肿瘤分化程度、肿瘤大小及淋巴结转移均无明显关系(P>0.05)。CIP2A蛋白阳性表达组患者的总生存时间短于阴性组患者,差异有统计学意义(P=0.001)。CIP2A蛋白表达、TNM分期和肿瘤分化程度是NSCLC患者预后的独立影响因素(P<0.05)。结论:CIP2A蛋白在NSCLC组织中高表达,且其阳性表达与NSCLC患者预后有关。
Objective: To investigate the expression of CIP2A in non-small cell lung cancer (NSCLC) and its clinical significance. Methods: The expression of CIP2A protein in 97 cases of NSCLC tissues and its corresponding paracancerous tissues was detected by immunohistochemistry. The relationship between the expression of CIP2A protein and the clinicopathological features and prognosis of NSCLC patients was analyzed. Results: The positive expression rate of CIP2A protein in NSCLC tissues was significantly higher than that in the corresponding paracancerous tissues [(76.3%, 74/97) [5.2% (5/97)], with significant difference (P <0.01). The positive expression of CIP2A protein had no significant relationship with age, sex, smoking status, histological type, TNM stage, tumor differentiation, tumor size and lymph node metastasis in patients with NSCLC (P> 0.05). The overall survival of patients with CIP2A positive expression was shorter than that of negative patients (P = 0.001). CIP2A protein expression, TNM stage and tumor differentiation were independent prognostic factors in patients with NSCLC (P <0.05). Conclusion: CIP2A protein is highly expressed in NSCLC tissues, and the positive expression of CIP2A protein is associated with the prognosis of NSCLC patients.